---
A Subscription Approach to Weight Loss Medication
The GLP-1 weight loss drug market is undergoing a significant shift in how patients access and pay for their medications. A new multi-month subscription plan for the Wegovy brand — available as both an injection pen and a pill — aims to solve one of the most persistent barriers to long-term treatment: unpredictable costs.
The Problem of Price Uncertainty
One of the major challenges facing patients on GLP-1 weight loss drugs has been the inconsistency of pricing. Depending on the pharmacy, the dosage level, and the payment method, costs can vary significantly from month to month. This is especially true for injectable versions of these drugs, which require patients to escalate through different dosage levels over time. As the dosage increases, so can the price — creating a moving target that makes budgeting difficult for self-pay patients.
Research has shown that a substantial percentage of people who begin GLP-1 therapy do not stay on it long-term. While some discontinue because they have reached their weight loss goals, many others drop off due to accessibility issues and fluctuating costs. This attrition represents both a public health concern and a commercial problem for the drug's manufacturer.
How the Subscription Plan Works
The new program is available through telehealth providers including Ro, Weight Watchers, LifeMD, Hims & Hers, and Sesame, with more platforms expected to follow. Eligible self-pay patients can choose from three tiers:
For the injection pen:
- 3-month plan: $329/month
- 6-month plan: $299/month
- 12-month plan: $249/month (saving up to $1,200/year versus standard monthly pricing)
For the oral pill (launched in January under the same brand):
- 3-month plan: $289/month
- 6-month plan: $269/month
- 12-month plan: $249/month (saving up to $600/year)
The key appeal is the flat pricing structure. Regardless of what dosage level a patient is on — whether for the injection or the pill — the monthly cost remains the same throughout the subscription period. This predictability is designed to remove one of the biggest friction points in long-term adherence.
The Competitive Landscape
This pricing strategy arrives at a critical moment. The stock has been trading near four-year lows, and the company faces pressure on multiple fronts. Eli Lilly's competing injectable weight loss drug, Zepbound, is available at cash prices ranging from $299 to $499 per month. By offering the 12-month subscription at $249 per month, the new plan undercuts even the lowest tier of Lilly's pricing.
There is also the ongoing threat from compounding pharmacies, which have been selling copycat versions of these drugs at lower prices. Notably, one major telehealth platform that previously sold compounded knockoffs has now pivoted to offering the FDA-approved version through this very subscription model — a significant win for the branded product.
A Broader Trend
This move reflects a broader evolution in pharmaceutical commercialization. Rather than relying solely on insurance coverage and traditional pharmacy channels, drug manufacturers are increasingly adopting direct-to-consumer subscription models distributed through telehealth platforms. The approach mirrors pricing strategies common in software and streaming services: lock in customers with predictable, tiered pricing and reduce churn by lowering the barriers to staying enrolled.
For patients, the benefit is straightforward — knowing exactly what they will pay each month makes it easier to commit to a long-term treatment plan. For the manufacturer, improved retention translates directly into more predictable revenue and a stronger competitive position in an increasingly crowded market. Whether this model becomes the standard for high-cost chronic medications remains to be seen, but it represents a meaningful step toward making weight loss treatment more accessible and financially manageable.